European Journal of Breast Health (Oct 2017)

Reliable Biomarkers to Identify New and Recurrent Cancer

  • Edward R. Sauter

DOI
https://doi.org/10.5152/ejbh.2017.3635
Journal volume & issue
Vol. 13, no. 4
pp. 162 – 167

Abstract

Read online

Breast cancer is the most frequent cancer detected throughout both the developing and the developed world. Its incidence is on the rise in the developing world. Great strides have been made in developing biomarkers to guide therapy for women diagnosed with breast cancer. Far fewer advances have occurred with biomarker development for the early diagnosis of breast cancer. Standard screening for new and recurrent breast cancer involves clinical breast exam and breast imaging. There are no Food and Drug Administration (FDA) approved noninvasive body fluid tests for the early detection of new or recurrent breast cancer. Promising biomarker approaches include multianalyte testing of tissue for individuals diagnosed with breast cancer and body fluid analysis for both at risk women and to monitor individuals after treatment.

Keywords